

UnitedHealthcare Community Plan of Kentucky **Medical Policy Update Bulletin: February 2023**

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

Medical Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|----------------|
| Apheresis (for Kentucky Only) | Revised | Mar. 1, 2023 |
| Bariatric Surgery (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Genetic Testing for Hereditary Cancer (for Kentucky Only) | Revised | Mar. 1, 2023 |
| Hepatitis Screening (for Kentucky Only) | Updated | Mar. 1, 2023 |
| Negative Pressure Wound Therapy (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Neurophysiologic Testing and Monitoring (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Pharmacogenetic Panel Testing (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Plagiocephaly and Craniosynostosis Treatment (for Kentucky Only) | Updated | Apr. 1, 2023 |
| Skin and Soft Tissue Substitutes (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Temporomandibular Joint Disorders (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Total Artificial Disc Replacement for the Spine (for Kentucky Only) | Revised | Mar. 1, 2023 |
| Vagus and External Trigeminal Nerve Stimulation (for Kentucky Only) | Revised | Apr. 1, 2023 |
| Visual Information Processing Evaluation and Orthoptic and Vision Therapy (for Kentucky Only) | Updated | Apr. 1, 2023 |

Medical Benefit Drug Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|----------------|
| Hemgenix® (Etranacogene Dezaparvovec-Drlb) | New | Mar. 1, 2023 |
| Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) | Revised | Mar. 1, 2023 |
| Leqvio® (Inclisiran) | Revised | Mar. 1, 2023 |
| Maximum Dosage and Frequency | Revised | Mar. 1, 2023 |
| Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised | Apr. 1, 2023 |
| Review at Launch for New to Market Medications | Revised | Mar. 1, 2023 |
| RNA-Targeted Therapies (Amvuttra [™] and Onpattro [®]) | Revised | Mar. 1, 2023 |
| Spevigo® (Spesolimab-Sbzo) | New | Mar. 1, 2023 |
| Tzield [™] (Teplizumab-Mzwv) | New | Mar. 1, 2023 |

General Information

The inclusion of a health service (e.g., test, drug, device or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Community Plan of Kentucky Medical Policy, Medical Benefit Drug Policy, Coverage Determination Guideline, and Utilization Review Guideline updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan of Kentucky Medical Policies, Medical Benefit Drug Policies, Coverage Determination Guidelines, and Utilization Review Guidelines is available at UHCprovider.com/Kentucky > Medicaid (Community Plan) > Current Policies and Clinical Guidelines > UnitedHealthcare Community Plan of Kentucky Medical & Drug Policies and Coverage Determination Guidelines.